<DOC>
	<DOCNO>NCT00395252</DOCNO>
	<brief_summary>This open-label , non-randomized Phase II study evaluate immunochemotherapy patient R0 OR R1-resected pancreatic cancer .</brief_summary>
	<brief_title>Safety Efficacy Therapy Gemcitabine Erbitux® R0 R1 Resected Pancreatic Cancer</brief_title>
	<detailed_description>Available study data indicate possible benefit adjuvant chemotherapy patient resect pancreatic cancer . The optimal therapy regimen yet determine . Based experience cetuximab ( Erbitux® ) gemcitabine advance pancreatic cancer gemcitabine adjuvant therapy , aim study evaluate feasibility combine treatment cetuximab gemcitabine patient R0 R1-resectable pancreatic cancer evaluate disease free survival increase addition EGFR-targeted therapy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Provided sign write informed consent . Men woman age &gt; 18 year Histologically confirm R0 OR R1 resect ductal adenocarcinoma pancreas Life expectancy &gt; 12 week Patients performance status ECOG ≤ 2 Patients without metastasis Women child bear potential ( WOCP ) unwilling unable use acceptable method avoid pregnancy entire study period followup 4 week study . Women pregnant breastfeeding . Women positive pregnancy test enrollment prior study drug administration . Dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent . Any concurrent malignancy nonmelanoma skin cancer , carcinoma situ cervix . ( Patients previous malignancy without evidence disease &gt; 5 year allow enter trial ) . Inadequate hematologic function define absolute neutrophil count ( ANC ) &lt; 1,500/mm³ , platelet count &lt; 100,000/mm³ hemoglobin &lt; 9 g/dL . Inadequate hepatic function define upper limit normal ( ULN ) , AST ALT level &gt; 5 time ULN . Serum bilirubin &gt; 1.5 time ULN . Inadequate renal function define serum creatinine &gt; 1.5 time ULN . Prior cetuximab therapy target EGF pathway . Prior antibody therapy . Any known allergic reaction cetuximab . Any concurrent chronic systemic immune therapy , radiation therapy , hormonal therapy ( except physiological replacement ) , investigational agent . HIV infection . Having participate another clinical trial precede 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>phase 2</keyword>
	<keyword>R0 R1 resect Adenocarcinoma Pancreas</keyword>
</DOC>